Table 3.
Univariable and multivariable analysis of progression-free survival (PFS) and overall survival (OS) in aBC. Model 1 included statistically significant clinical variables and raw baseline factors values, while model 2 had significant clinical variables and baseline standardised values.
| HR (±95% CI) | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| PFS | OS | PFS | OS | ||
| Model 1 | Model 2 | Model 1 | |||
| Age [yrs] | 0.98 (0.94–1.01) |
0.98 (0.95–1.02) |
- | - | - |
| Diabetes mellitus | 1.64 (0.74–3.64) |
1.19 (0.52–2.73) |
- | - | - |
| Grade 3 vs. 2 | 1.52 (0.66–3.51) |
2.27 (0.94–5.51) $ |
- | - | 1.10 (0.4–3.09) |
| Multiple organ metastasis | 1.78 (0.72–4.40) |
2.70 (1.01–7.25) * |
- | - | 3.73 (1.24–11.21) * |
| Luminal HER2 negative | 1.27 (0.58–2.77) |
2.06 (0.86–4.94) |
- | - | - |
| Bone metastasis | 1.02 (0.50–2.07) |
1.40 (0.65–3.04) |
- | - | - |
| Liver metastasis | 2.04 (0.98–4.28) $ |
3.06 (1.38–6.82) # |
1.32 (0.53–3.31) |
2.01 (0.93–4.37) $ |
1.89 (0.70–5.15) |
| Brain metastasis | 1.88 (0.64–5.49) |
2.86 (0.93–8.82) $ |
- | - | - |
| Transtuzumab ± peruzumab therapy (HER2 positive) | 0.36 (0.14–0.96) * |
0.20 (0.06–0.70) * |
0.81 (0.31–2.08) |
0.98 (0.42–2.27) |
1.56 (0.55–4.39) |
| HT vs. CTH | 0.58 (0.22–1.53) |
0.74 (0.28–1.96) |
- | - | - |
| Baseline | |||||
| sE-selectin > 21.0 ng/mL | 1.66 (0.79–3.47) |
1.55 (0.71–3.36) |
- | - | - |
| sP-selectin > 38.1 ng/mL | 0.57 (0.27–1.17) |
0.61 (0.28–1.35) |
- | - | - |
| sVCAM-1 > 624.6 ng/mL | 1.96 (0.92–4.18) $ |
1.96 (0.91–4.21) $ |
- | - | 2.59 (1.15–5.82) * |
| sICAM-1 > 388.5 ng/mL | 2.07 (1.01–4.24) * |
1.42 (0.66–3.08) |
2.07 (0.90–4.72) $ |
- | - |
| EpCAM > 0.76 ng/mL | 0.70 (0.33–1.45) |
1.23 (0.55–2.74) |
- | - | - |
| sIL6Ra > 3.38 ng/mL | 0.74 (0.36–1.55) |
0.71 (0.32–1.58) |
- | - | - |
| sTNF-R1 > 0.84 ng/mL | 0.83 (0.41–1.70) |
1.39 (0.65–2.99) |
- | - | - |
| sTNF-R2 > 1.95 ng/mL | 2.48 (1.16–5.30) * |
1.88 (0.87–4.06) |
2.48 (1.16–5.30) * |
- | - |
| sE-selectin per 1-SD | 1.17 (0.85–1.63) |
1.30 (0.91–1.85) |
- | - | - |
| sP-selectin per 1-SD | 0.76 (0.48–1.20) |
0.87 (0.55–1.37) |
- | - | - |
| sVCAM-1 per 1-SD | 1.21 (0.86–1.70) |
1.24 (0.88–1.75) |
- | - | - |
| sICAM-1 per 1-SD | 1.60 (1.08–2.38) * |
1.18 (0.82–1.68) |
- | 0.90 (0.62–1.30) |
- |
| EpCAM per 1-SD | 0.88 (0.58–1.31) |
1.28 (0.84–1.95) |
- | - | - |
| sIL6Ra per 1-SD | 0.73 (0.48–1.12) |
0.71 (0.44–1.15) |
- | - | - |
| sTNF-R1 per 1-SD | 0.78 (0.49–1.23) |
0.92 (0.56–1.53) |
- | - | - |
| sTNF-R2 per 1-SD | 1.29 (0.96–1.74) |
1.18 (0.88–1.59) |
- | - | - |
$ p < 0.1, * p < 0.05, # p < 0.01.